Rivaroxaban (Xarelto) Market: Facing The Patent Cliff And Strategic Opportunities

Published: Sep, 2025
Report ID: GVR-MT-100426
Format: PDF/Excel databook

No. of Pages/Datapoints: 110
Report Coverage: 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
  1.2. Segment Definitions
  1.3. Estimates and Forecast Timeline
  1.4. Research Methodology
  1.5. Information Procurement
1.5.1. Purchased Database
  1.5.2. GVR’s Internal Database
  1.5.3. Secondary Sources
  1.5.4. Primary Research
  1.6. Information Analysis
  1.6.1. Data Analysis Models
  1.7. Market Formulation & Data Visualization
  1.8. Model Details
  1.8.1. Commodity Flow Analysis
  1.9. List of Secondary Sources
  1.10. Objectives
Chapter 2. Executive Summary
  2.1. Market Snapshot
  2.2. Segment Snapshot
  2.3. Competitive Landscape Snapshot
Chapter 3. Rivaroxaban (Xarelto) Market Variables, Trends, & Scope
  3.1. Market Lineage Outlook
  3.2. Market Dynamics
  3.2.1. Market Driver Analysis
  3.2.2. Market Restraint Analysis
  3.3. Business Environment Analysis
  3.3.1. Industry Analysis – Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
  3.3.1.2. Buyer Power
  3.3.1.3. Substitution Threat
  3.3.1.4. Threat of New Entrants
  3.3.1.5. Competitive Rivalry
  3.3.2. PESTLE Analysis
  3.3.3. Pipeline Analysis
  3.3.3.1. Global Rivaroxaban (Xarelto) Branded Drug Market 2021 - 2033 (USD Million)
  3.3.3.2. Global Rivaroxaban (Xarelto) Generic Drug Market 2021 - 2033 (USD Million)
  3.3.4. Pricing Analysis
Chapter 4. Rivaroxaban (Xarelto) Market: Indication Business Analysis
  4.1. Indication Market Share, 2024 & 2033
  4.2. Indication Segment Dashboard
  4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  4.4. Non-Valvular Atrial Fibrillation (NVAF)
  4.4.1. Non-Valvular Atrial Fibrillation (NVAF) Market, 2021 - 2033 (USD Million)
  4.5. Deep Vein Thrombosis (DVT)
  4.5.1. Deep Vein Thrombosis (DVT) Market, 2021 - 2033 (USD Million)
  4.6. Others
  4.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Rivaroxaban (Xarelto) Market: Regional Estimates & Trend Analysis
  5.1. Regional Market Share Analysis, 2024 & 2033
  5.2. Regional Market Dashboard
  5.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  5.4. North America
  5.5. Europe
  5.6. Asia Pacific
  5.7. Latin America
  5.8. Middle East and Africa
Chapter 6. Competitive Landscape
  6.1. Company Profile
  6.1.1. Bayer AG
  6.1.1.1. Overview
  6.1.1.2. Financial Performance
  6.1.1.3. Strategic Mapping
  6.1.2. Janssen Pharmaceuticals (Johnson & Johnson)
  6.1.2.1. Overview
  6.1.2.2. Financial Performance
  6.1.2.3. Strategic Mapping
  6.1.3. Lupin Pharmaceuticals
  6.1.3.1. Overview
  6.1.3.2. Financial Performance
  6.1.3.3. Strategic Mapping
  6.1.4. Taro Pharmaceuticals
  6.1.4.1. Overview
  6.1.4.2. Financial Performance
  6.1.4.3. Strategic Mapping
  6.1.5. Alembic Pharmaceuticals
  6.1.5.1. Overview
  6.1.5.2. Financial Performance
  6.1.5.3. Strategic Mappin

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Rivaroxaban (Xarelto) market, by region, 2021 - 2033 (USD Million)
Table 4 North America Rivaroxaban (Xarelto) market, by Indication, 2021 - 2033 (USD Million)
Table 5 Europe Rivaroxaban (Xarelto) market, by Indication, 2021 - 2033 (USD Million)
Table 6 Asia Pacific Rivaroxaban (Xarelto) market, by Indication, 2021 - 2033 (USD Million)
Table 7 Latin America Rivaroxaban (Xarelto) market, by Indication, 2021 - 2033 (USD Million)
Table 8 Middle East & Africa Rivaroxaban (Xarelto) market, by Indication, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Rivaroxaban (Xarelto) market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and disease outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Rivaroxaban (Xarelto) market dynamics
Fig. 12 Rivaroxaban (Xarelto) market: Porter’s five forces analysis
Fig. 13 Rivaroxaban (Xarelto) market: PESTLE analysis
Fig. 14 Indication market, 2021 - 2033 (USD Million)
Fig. 15 Non-Valvular Atrial Fibrillation (NVAF) market, 2021 - 2033 (USD Million)
Fig. 16 Deep Vein Thrombosis (DVT) market, 2021 - 2033 (USD Million)
Fig. 17 Others market, 2021 - 2033 (USD Million)
Fig. 18 Rivaroxaban (Xarelto) market revenue, by region
Fig. 19 Regional marketplace: Key takeaways
Fig. 20 North America Rivaroxaban (Xarelto) market, 2021 - 2033 (USD Million)
Fig. 21 Europe Rivaroxaban (Xarelto) market, 2021 - 2033 (USD Million)
Fig. 22 Asia Pacific Rivaroxaban (Xarelto) market, 2021 - 2033 (USD Million)
Fig. 23 Latin America Rivaroxaban (Xarelto) market, 2021 - 2033 (USD Million)
Fig. 24 MEA Rivaroxaban (Xarelto) market, 2021 - 2033 (USD Million)
Fig. 25 Company categorization
Fig. 26 Company market position analysis
Fig. 27 Strategic framework

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.